Circulating endothelial cell and prognosis after cardiopulmonary bypass

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCS-09000398

Enrollment

Unknown

Registered

2009-05-17

Start date

2009-06-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic heart disease

Interventions

observing group:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adult patients that come to department of cardiothoracic surgery of West China Hospital and receive valve replacement surgery, and sign Informed Consent.

Exclusion criteria

Exclusion criteria: 1. coronary artery disease; 2. thrombosis and embolism disease; 3. Hematologic disease; 4. other malignancy, prior radio- or chemotherapy; 5. Use of corticosteroids or immune suppression therapy; 6. Participation in other clinical study which has not ended yet; 7. Pregnancy, birth or lactation period <6 months ago; 8. not the first time receiving cardiac surgery under cardiopulmonary bypass; 9. Severe renal insufficiency; 10. Severe hepatic insufficiency.

Design outcomes

Primary

Measure	Time frame
the number of circulating endothelial cell;	—

Secondary

Measure	Time frame
Indices of function of liver, kidny, brain, heart and lung;	—

Countries

China

Contacts

Public ContactLei Du

dulei1972@yahoo.com.cn+86 0 18982295596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026